Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 5/20 | 0.47 |
| ▸ | P2RX2 | Q9UBL9 | 5/20 | 0.47 |
| ▸ | RAF1 | P04049 | 6/20 | 0.39 |
| ▸ | BRAF | P15056 | 5/20 | 0.39 |
| ▸ | WDR5 | P61964 | 1/20 | 0.39 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3805195 | 1.00 | P2RX3 (0.47) | P2RX3P2RX2RAF1BRAFWDR5 | |
| SCHEMBL13095560 | 0.84 | P2RX3 (0.46) | P2RX3P2RX2RAF1BRAFWDR5 | |
| SCHEMBL3659347 | 0.76 | KMO (0.49) | P2RX3P2RX2RAF1BRAFLMNA | |
| SCHEMBL10243307 | 0.70 | P2RX3 (0.48) | P2RX3P2RX2MAPT | |
| SCHEMBL10243217 | 0.70 | P2RX3 (0.51) | P2RX3P2RX2 | |
| SCHEMBL2259992 | 0.70 | NPC1 (0.38) | P2RX3P2RX2RAF1BRAF | |
| SCHEMBL16440127 | 0.70 | NPC1 (0.38) | P2RX3P2RX2RAF1BRAF | |
| SCHEMBL4333637 | 0.69 | P2RX3 (0.51) | P2RX3P2RX2 | |
| SCHEMBL2170927 | 0.68 | P2RX3 (0.51) | P2RX3P2RX2WDR5 | |
| SCHEMBL10244227 | 0.67 | P2RX3 (0.48) | P2RX3P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8247401-B2 | P2X3 receptor antagonists for treatment of pain | MERCK SHARP & DOHME CORP. (US) | 2012-08-21 | — | — | US | claimed |
| US-20100266714-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME LLC | 2010-10-21 | — | — | US | claimed |
| EP-2215049-B1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME (US) | 2019-06-12 | — | — | EP | disclosed |
| US-8247401-B2 | P2X3 receptor antagonists for treatment of pain | MERCK SHARP & DOHME CORP. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20100266714-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME LLC | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100266714-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | P2RX3, P2RX1, P2RX2 | P2RX3 1/4885P2RX2 3/4885RAF1 3797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.